Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Teva Uses the Agilent TRS100 to Achieve Regulatory Milestone for Content Uniformity Testing with the FDA

publication date: Jul 25, 2022
 | 
author/source: Agilent Technologies

teva-uses-the-agilent-trs100-achieve-regulatory 

Agilent’s unique technology for content uniformity workflow creates a major customer impact

Agilent Technologies Inc. (NYSE: A) announce that the FDA has approved a content uniformity (CU) method using the Agilent TRS100 Raman quantitative pharmaceutical analysis system.

The submitting company, Teva Pharmaceutical Industries Ltd., is an Agilent Raman spectroscopy customer and global leader in generic and biopharmaceuticals. In 2021, the U.S. Food and Drug Administration (FDA) approved the company’s CU method application, which was developed using the TRS100 system.

Content uniformity testing is one of several mandatory batch release quality control checks. Determining how much active pharmaceutical ingredient (API) is inside a tablet or capsule, and whether the API is uniform across a batch, is important for quality metrics. Spectroscopic technologies, such as the TRS100, present a fast, whole sample analysis, negating the sample preparation stages, to complete the test in a matter of minutes.

“The FDA approval of a TRS100 method for content uniformity testing by Teva is a great achievement for Teva, as well as for Agilent, and a key milestone for the product itself,” said Geoff Winkett, vice president of Agilent’s Molecular Spectroscopy division. “Teva joins other customers who have adopted this technology for CU testing for all the benefits it brings. It is a substantial investment to change manufacturing and QC processes, and an FDA approval minimizes the perceived risk of adopting this new technology.”

The approval of this CU method using the TRS100 is specific to Teva. 

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide.

 

Recent news from Agilent Technologies

 


If you have not logged into the website then please enter your details below.



 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events